Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells |
| |
| Affiliation: | 1. Center for Cellular Immunotherapy, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;2. Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA;1. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA;2. Texas Children''s Cancer Center, Baylor College of Medicine, Houston, Texas, USA;3. Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA;1. Hematology Unit, AO, Cosenza, Italy;2. Biotecnology Research Unit, Aprigliano, Cosenza, Italy;3. SS di Diagnostica Molecolare IRCCS S. Martino-IST, Genova, Italy;4. Department of Clinical and Community Science, University of Milan, Milano, Italy;5. Scientific Division, IRCCS S. Martino-National Cancer Institute, Genova, Italy;6. Hematology Division, IRCCS Foundation Cà Granda, Policlinico Hospital, Milan, Italy;7. Hematology Unit, Maria Nuova Civil Hospital, Reggio Emilia, Italy;8. Hematology–Oncology Unit, Garibaldi-Nesima Hospital, Catania, Italy;9. Hematology Unit, AO, Reggio Calabria, Italy;10. Hematology Unit, University of Messina, MessinaItaly;11. Hematology Unit, AO, Catanzaro, Italy;1. Department of Hematology, Medical University of Lodz, Lodz, Poland;2. Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland |
| |
| Abstract: | Adoptive cell immunotherapy for the treatment of chronic lymphocytic leukemia (CLL) has heralded a new era of synthetic biology. The infusion of genetically engineered, autologous chimeric antigen receptor (CAR) T cells directed against CD19 expressed by normal and malignant B cells represents a novel approach to cancer therapy. The results of recent clinical trials of CAR T cells in relapsed and refractory CLL have demonstrated long-term disease-free remissions, underscoring the power of harnessing and redirecting the immune system against cancer. This review will briefly summarize T-cell therapies in development for CLL disease. We discuss the role of T-cell function and phenotype, T-cell culture optimization, CAR design, and approaches to potentiate the survival and anti-tumor effects of infused lymphocytes. Future efforts will focus on improving the efficacy of CAR T cells for the treatment of CLL and incorporating adoptive cell immunotherapy into standard medical management of CLL. |
| |
| Keywords: | CAR CLL Immunotherapy T cell Leukemia |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
